Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment.

Harbour BioMed out-licensed global rights for a pre-clinical bispecific candidate to AstraZeneca in a $350 million agreement. Harbour BioMed will receive $25 million upfront and as much as $325 million in milestones, plus royalties.